Drug, across the briefings

Cabozantinib across 7 cancers

Cabozantinib appears in 7 of the briefings; its FDA label names 3 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Hepatocellular carcinoma	label names disease	approved on MET, KDR	33	18
Kidney cancer	label names disease	approved on KDR, MET	72	45
Thyroid cancer	label names disease		—	—
Gastric cancer		approved on MET, KDR	4	2
Lung cancer		approved on MET	20	7
Osteosarcoma		approved on KDR	9	6
Uveal melanoma		approved on MET	1	0

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.